Vaxil BioTherapeutics Overview

  • Founded
  • 2006
Founded
  • Status
  • Public
  • Stock Symbol
  • VXL
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.07
  • (As of Friday Closing)

Vaxil BioTherapeutics General Information

Description

Vaxil Bio Ltd is an immuno-oncology biotechnology company. It is principally engaged in research and development of the ImMucin vaccine to treat cancer. ImMucin is the company's immunotherapy product. The organization is focused on developing novel immunotherapies including neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. Its VaxHit platform allows identification, isolation, and production of specific antigen-based immunotherapy products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
TSX
Primary Office
  • First Canadian Place, 34th Floor
  • 100 King Street West
  • Toronto, Ontario M5X 1A9
  • Canada

Vaxil BioTherapeutics Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxil BioTherapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.07 $0.07 $0.05 - $0.61 $8.78M 116M 1.44M

Vaxil BioTherapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 26,707 26,707 2,241 1,154
Revenue 0 0 0 0
EBITDA (961) (961) (786) (760)
Net Income (1,012) (1,012) (869) (808)
Total Assets 1,303 1,303 157 653
Total Debt 7 7 57 4
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vaxil BioTherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaxil BioTherapeutics‘s full profile, request access.

Request a free trial

Vaxil BioTherapeutics Executive Team (6)

Name Title Board Seat Contact Info
David Goren Chief Executive Officer & Chairman
Gadi Levin Chief Financial Officer & Board Member
You’re viewing 2 of 6 executive team members. Get the full list »

Vaxil BioTherapeutics Board Members (5)

Name Representing Role Since
Ari Kellen Vaxil BioTherapeutics Board Member 000 0000
David Goren Vaxil BioTherapeutics Chief Executive Officer & Chairman 000 0000
Gadi Levin Self Chief Financial Officer & Board Member 000 0000
Shawn Langer MD Self Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Vaxil BioTherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vaxil BioTherapeutics‘s full profile, request access.

Request a free trial

Vaxil BioTherapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000000 29-Feb-2016 000000000000000000 Multi-line Mining
To view Vaxil BioTherapeutics’s complete acquisitions history, request access »